Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Urology|July 13, 2022
Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary IncontinenceChristopher J Chermansky, Holly E Richter, Karny Jacoby, et al.
Neurourology and Urodynamics|December 11, 2020
OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in childrenPaul F Austin, Israel Franco, Eric Dobremez, et al.
The Journal of Urology|January 19, 2023
Long-term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children With Neurogenic Detrusor OveractivityIsrael Franco, Piet B Hoebeke, Eric Dobremez, et al.
Urology|January 8, 2013
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysisMichael Kennelly, Roger Dmochowski, Karen Ethans, et al.
Ethnicity & Disease|December 2, 2005
Cardiovascular disease event classification in the Jackson Heart Study: methods and proceduresEmmanuel Keku, Wayne Rosamond, Herman A Taylor, et al.
The Journal of Urology|April 17, 2012
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivityDavid Ginsberg, Angelo Gousse, Veronique Keppenne, et al.
Neurourology and Urodynamics|November 27, 2015
Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension studyMichael Kennelly, Roger Dmochowski, Heinrich Schulte-Baukloh, et al.
Neurology|July 22, 2018
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MSMark Tullman, Emmanuel Chartier-Kastler, Alfred Kohan, et al.
The Journal of Urology|April 4, 2016
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year StudyVictor W Nitti, David Ginsberg, Karl-Dietrich Sievert, et al.
Advances in Therapy|September 28, 2013
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiologyDavid Ginsberg, Francisco Cruz, Sender Herschorn, et al.
Pageof 3